Alzheimer’s Drug Discovery Foundation: Prevention

If you are interested in the following opportunity, please contact Carole King at [email protected].

• LOI due: September 14, 2026
• Budget: $5,000,000 (no indirects)
• Project period: Multi-year

Funds human studies on precision prevention, combination therapies, and comparative effectiveness to reduce Alzheimer’s and related dementia risk.  Eligible studies target primary or secondary prevention populations, focus on modifiable risk factors, and measure outcomes such as cognition or biomarkers.  Lifestyle-only interventions are excluded, but combinations with drugs, supplements, or devices are eligible.  Priority goes to novel or repurposed therapeutics with strong commercial or IP potential.